PT  - JOURNAL ARTICLE
AU  - HENDRIK HEERS
AU  - PATRICK DE GEETER
AU  - PETER J. GOEBELL
AU  - ULLRICH MATZ
AU  - WITO DE SCHULTZ
AU  - BIRGIT EDLICH
AU  - MARGITTA RETZ
AU  - AXEL HEGELE
TI  - Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma – Subgroup Analysis of an Observational Study
DP  - 2017 Nov 01
TA  - Anticancer Research
PG  - 6437--6442
VI  - 37
IP  - 11
4099  - http://ar.iiarjournals.org/content/37/11/6437.short
4100  - http://ar.iiarjournals.org/content/37/11/6437.full
SO  - Anticancer Res2017 Nov 01; 37
AB  - Background/Aim: Despite an expected prognostic disadvantage for upper tract versus lower tract metastatic urothelial carcinomas (UTUC/LTUC), only few studies have been conducted to elucidate potential differences in chemotherapy treatment. Patients and Methods: A post-hoc subgroup analysis of a non-interventional study investigating vinflunine after failure of a platinum-based chemotherapy in metastatic/locally advanced UC patients was performed. Results: A total of 18 and 59 out of 77 patients had UTUC and LTUC, respectively. The effectiveness of vinflunine treatment was comparable with an overall response rate of 22.2% and 23.7% respectively and a median progression-free survival of 2.76 months in both groups. Median overall survival was 5.0 months in UTUC compared to 8.2 months in the LTUC group (p=0.478). The safety profile was in accordance with previous vinflunine experiences, with a comparable frequency of adverse events in both groups. Conclusion: Vinflunine can be applied in the 2nd line for UC regardless of the primary tumor localization.